XML 98 R65.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Equity and Long-term Investments and Fair Value Measurements - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Dec. 31, 2024 | Dec. 31, 2023
--- | --- | ---
Fair Value Measurements |  |
Contingent value rights | $ 0 | $ 359
Recurring basis |  |
Assets |  |
Total assets measured at estimated fair value | 765,285 | 705,963
Recurring basis | Money market funds |  |
Assets |  |
Total assets measured at estimated fair value | 289,441 | 170,706
Recurring basis | Equity investments and Money market funds | ISP Fund LP |  |
Assets |  |
Total assets measured at estimated fair value | 255,658 | 311,812
Recurring basis | Term loan investment | Armata July 2023 Term Loan |  |
Assets |  |
Total assets measured at estimated fair value | 30,197 | 27,044
Recurring basis | Term loan investment | Armata March 2024 Term Loan |  |
Assets |  |
Total assets measured at estimated fair value | 39,275 |
Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 |  |
Assets |  |
Total assets measured at estimated fair value | 529,393 | 503,162
Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Money market funds |  |
Assets |  |
Total assets measured at estimated fair value | 289,441 | 170,706
Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investments and Money market funds | ISP Fund LP |  |
Assets |  |
Total assets measured at estimated fair value | 193,560 | 251,207
Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Term loan investment | Armata July 2023 Term Loan |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Term loan investment | Armata March 2024 Term Loan |  |
Assets |  |
Total assets measured at estimated fair value | 0 |
Recurring basis | Significant Other Observable Inputs, Level 2 |  |
Assets |  |
Total assets measured at estimated fair value | 5,901 | 35,297
Recurring basis | Significant Other Observable Inputs, Level 2 | Money market funds |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investments and Money market funds | ISP Fund LP |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
Recurring basis | Significant Other Observable Inputs, Level 2 | Term loan investment | Armata July 2023 Term Loan |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
Recurring basis | Significant Other Observable Inputs, Level 2 | Term loan investment | Armata March 2024 Term Loan |  |
Assets |  |
Total assets measured at estimated fair value | 0 |
Recurring basis | Significant Unobservable Inputs, Level 3 |  |
Assets |  |
Total assets measured at estimated fair value | 229,991 | 167,504
Recurring basis | Significant Unobservable Inputs, Level 3 | Money market funds |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investments and Money market funds | ISP Fund LP |  |
Assets |  |
Total assets measured at estimated fair value | 62,098 | 60,605
Recurring basis | Significant Unobservable Inputs, Level 3 | Term loan investment | Armata July 2023 Term Loan |  |
Assets |  |
Total assets measured at estimated fair value | 30,197 | 27,044
Recurring basis | Significant Unobservable Inputs, Level 3 | Term loan investment | Armata March 2024 Term Loan |  |
Assets |  |
Total assets measured at estimated fair value | 39,275 |
Nonrecurring basis |  |
Fair Value Measurements |  |
Contingent value rights |  | 359
Liabilities |  |
Total liabilities at estimated fair value |  | 427,836
Nonrecurring basis | Debt |  |
Fair Value Measurements |  |
Total fair value of debt | 473,566 | 427,477
Nonrecurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 |  |
Fair Value Measurements |  |
Contingent value rights |  | 0
Liabilities |  |
Total liabilities at estimated fair value |  | 0
Nonrecurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Debt |  |
Fair Value Measurements |  |
Total fair value of debt | 0 | 0
Nonrecurring basis | Significant Other Observable Inputs, Level 2 |  |
Fair Value Measurements |  |
Contingent value rights |  | 0
Liabilities |  |
Total liabilities at estimated fair value |  | 427,477
Nonrecurring basis | Significant Other Observable Inputs, Level 2 | Debt |  |
Fair Value Measurements |  |
Total fair value of debt | 473,566 | 427,477
Nonrecurring basis | Significant Unobservable Inputs, Level 3 |  |
Fair Value Measurements |  |
Contingent value rights |  | 359
Liabilities |  |
Total liabilities at estimated fair value |  | 359
Nonrecurring basis | Significant Unobservable Inputs, Level 3 | Debt |  |
Fair Value Measurements |  |
Total fair value of debt | 0 | 0
Nonrecurring basis | 2025 Notes | Debt |  |
Fair Value Measurements |  |
2025 Notes | 222,353 | 200,407
Nonrecurring basis | 2025 Notes | Quoted Price in Active Markets for Identical Assets, Level 1 | Debt |  |
Fair Value Measurements |  |
2025 Notes | 0 | 0
Nonrecurring basis | 2025 Notes | Significant Other Observable Inputs, Level 2 | Debt |  |
Fair Value Measurements |  |
2025 Notes | 222,353 | 200,407
Nonrecurring basis | 2025 Notes | Significant Unobservable Inputs, Level 3 | Debt |  |
Fair Value Measurements |  |
2025 Notes | 0 | 0
Nonrecurring basis | 2028 Notes | Debt |  |
Fair Value Measurements |  |
2028 Notes | 251,213 | 227,070
Nonrecurring basis | 2028 Notes | Quoted Price in Active Markets for Identical Assets, Level 1 | Debt |  |
Fair Value Measurements |  |
2028 Notes | 0 | 0
Nonrecurring basis | 2028 Notes | Significant Other Observable Inputs, Level 2 | Debt |  |
Fair Value Measurements |  |
2028 Notes | 251,213 | 227,070
Nonrecurring basis | 2028 Notes | Significant Unobservable Inputs, Level 3 | Debt |  |
Fair Value Measurements |  |
2028 Notes | 0 | 0
Armata | Recurring basis | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 42,095 | 51,883
Armata | Recurring basis | Equity investment | Common stock |  |
Assets |  |
Total assets measured at estimated fair value | 46,392 | 81,249
Armata | Recurring basis | Equity investment | Warrants |  |
Assets |  |
Total assets measured at estimated fair value | 5,901 | 35,297
Armata | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
Armata | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Common stock |  |
Assets |  |
Total assets measured at estimated fair value | 46,392 | 81,249
Armata | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Warrants |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Common stock |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Warrants |  |
Assets |  |
Total assets measured at estimated fair value | 5,901 | 35,297
Armata | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 42,095 | 51,883
Armata | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Common stock |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
Armata | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Warrants |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
InCarda | Recurring basis | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 436 |
InCarda | Recurring basis | Equity investment | Warrants |  |
Assets |  |
Total assets measured at estimated fair value | 59 |
InCarda | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 0 |
InCarda | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Warrants |  |
Assets |  |
Total assets measured at estimated fair value | 0 |
InCarda | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 0 |
InCarda | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Warrants |  |
Assets |  |
Total assets measured at estimated fair value | 0 |
InCarda | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 436 |
InCarda | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Warrants |  |
Assets |  |
Total assets measured at estimated fair value | 59 |
ImaginAb | Recurring basis | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 4,950 |
ImaginAb | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 0 |
ImaginAb | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 0 |
ImaginAb | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 4,950 |
Gate Neuroscience [Member] | Recurring basis | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 50,881 | 27,972
Gate Neuroscience [Member] | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
Gate Neuroscience [Member] | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | 0 | 0
Gate Neuroscience [Member] | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment |  |
Assets |  |
Total assets measured at estimated fair value | $ 50,881 | $ 27,972

X
- Definition Contingent value rights liability + References No definition available. + Details
Name: | inva_ContingentValueRightsLiability
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of long-term notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior debt has the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment. + References No definition available. + Details
Name: | inva_ConvertibleSeniorDebtFairValueDisclosures
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of asset recognized for present right to economic benefit. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_AssetsFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ConvertibleDebtFairValueDisclosures
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details
Name: | us-gaap_DebtInstrumentFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value of financial and nonfinancial obligations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_LiabilitiesFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=inva_EquityInvestmentsAndMoneyMarketFundsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=inva_IspFundLpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=inva_TermLoanInvestmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=inva_ArmataMarchTwoThousandTwentyFourTermLoanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ImaginabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |